Development of Fast Dissolving Oral Films Containing Lercanidipine HCl Nanoparticles in Semicrystalline Polymeric Matrix for Enhanced Dissolution and Ex Vivo Permeation

Research paper by Ankita D. Chonkar, J. Venkat Rao, Renuka S. Managuli, Srinivas Mutalik, Swapnil Dengale, Prateek Jain, N. Udupa

Indexed on: 06 Apr '16Published on: 05 Apr '16Published in: European Journal of Pharmaceutics and Biopharmaceutics


Lercanidipine is a vasoselective dihydropyridine calcium antagonist, mainly used for the treatment of hypertension and angina pectoris. However, it suffers from food dependent absorption, poor solubility, low permeability and considerable first pass metabolism, resulting in highly variable and low bioavailability of 10%. Nanoparticles of lercanidipine were incorporated in fast dissolving oral films (FDO) via preparation of nanosuspension by evaporative antisolvent precipitation method. Prepared nanosuspensions were incorporated in FDO without lyophilizing or spray drying. Two nanosuspensions containing PEG 400 and TPGS 1000 as stabilizers, selected further for incorporation in FDO. Physicochemical and mechanical properties of the optimised films were observed to be within acceptance criteria. SEM images as well as FTIR chemical images of oral films show uniform distribution of nano-particles in polymeric matrix. The DSC and XRD results proved the poorly crystalline nature of lercanidipine. However thermal processing of film induces crystallinity in hypromellose which results in embedding of amorphous drug nanoparticles in semicrystalline polymeric matrix. Superior dissolution and permeability properties of nanoparticles were confirmed by in-vitro dissolution studies and about 6.5 folds higher ex vivo drug permeation was observed from formulation through porcine buccal mucosa. This may give the clue for enhancement of bioavailability in vivo via improving orotransmucosal absorption.

Graphical abstract 10.1016/j.ejpb.2016.04.001.jpg
Figure 10.1016/j.ejpb.2016.04.001.0.jpg
Figure 10.1016/j.ejpb.2016.04.001.1.jpg
Figure 10.1016/j.ejpb.2016.04.001.2.jpg
Figure 10.1016/j.ejpb.2016.04.001.3.jpg
Figure 10.1016/j.ejpb.2016.04.001.4.jpg
Figure 10.1016/j.ejpb.2016.04.001.5.jpg
Figure 10.1016/j.ejpb.2016.04.001.6.jpg
Figure 10.1016/j.ejpb.2016.04.001.7.jpg